Biomea Fusion: Recent Rally May Not Last, Despite Upcoming …
WEB2 days ago · Biomea Fusion's lead candidate, BMF-219, shows potential in diabetes treatment but faces competition from superior GLP-1 drugs like Ozempic and Mounjaro. The recent lifting of the FDA clinical ...
Biomea Announces Formation of Global Scientific ... - Markets …
WEB2 days ago · Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically ...
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes …
WEBREDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced that the U.S. Food and Drug ...
Biomea Announces Formation of Global Scientific Advisory Board …
WEBInternational diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s evolving pipeline REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc.
Biomea upgraded by analysts after FDA lifts clinical hold
WEB5 days ago · Biomea Fusion (NASDAQ: BMEA) has received two analyst upgrades along with bullish comments from three other firms in the wake of Thursday’s news that the FDA has lifted a clinical hold on a ...
Biomea Fusion Highlights Recent Updates and Anticipated 2024 …
WEBJan 9, 2024 · Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases.
Biomea Fusion Hold Rating: FDA Clearance and Increased Price …
WEB6 days ago · Biomea Fusion upgraded to Buy from Neutral at Rodman & Renshaw; Truist sees fair value of $20-$50 per share after Biomea Fusion hold lifted; Biomea Fusion says FDA lifts clinical hold on BMF-219 ...
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes …
WEB5 days ago · BMEA. Biomea Fusion’s stock is on the up after the company plans to resume two clinical trials evaluating its therapy for type 1 (T1D) and 2 diabetes (T2D) after the US Food and Drug ...
Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 …
WEB6 days ago · (RTTNews) - Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing Phase I/II clinical trials of the Company's ...
Biomea Fusion, Inc. (BMEA) Latest Stock News & Headlines
WEBGet the latest Biomea Fusion, Inc. (BMEA) stock news and headlines to help you in your trading and investing decisions.